SG11201700882XA - Heterobicyclic compounds and their use for the treatment of tuberculosis - Google Patents
Heterobicyclic compounds and their use for the treatment of tuberculosisInfo
- Publication number
- SG11201700882XA SG11201700882XA SG11201700882XA SG11201700882XA SG11201700882XA SG 11201700882X A SG11201700882X A SG 11201700882XA SG 11201700882X A SG11201700882X A SG 11201700882XA SG 11201700882X A SG11201700882X A SG 11201700882XA SG 11201700882X A SG11201700882X A SG 11201700882XA
- Authority
- SG
- Singapore
- Prior art keywords
- tuberculosis
- treatment
- heterobicyclic compounds
- heterobicyclic
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014174528 | 2014-08-28 | ||
| PCT/JP2015/004371 WO2016031255A1 (en) | 2014-08-28 | 2015-08-28 | Heterobicyclic compounds and their use for the treatment of tuberculosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201700882XA true SG11201700882XA (en) | 2017-03-30 |
Family
ID=54105947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201700882XA SG11201700882XA (en) | 2014-08-28 | 2015-08-28 | Heterobicyclic compounds and their use for the treatment of tuberculosis |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US10053446B2 (en) |
| EP (1) | EP3186240B9 (en) |
| JP (1) | JP6625612B2 (en) |
| KR (1) | KR102418413B1 (en) |
| CN (1) | CN106795117B (en) |
| AP (1) | AP2017009788A0 (en) |
| AR (1) | AR101704A1 (en) |
| AU (1) | AU2015307873B2 (en) |
| BR (1) | BR112017003231B1 (en) |
| CA (1) | CA2959478C (en) |
| CY (1) | CY1122286T1 (en) |
| DK (1) | DK3186240T3 (en) |
| EA (1) | EA038414B1 (en) |
| ES (1) | ES2743788T3 (en) |
| HR (1) | HRP20191486T2 (en) |
| HU (1) | HUE045025T2 (en) |
| IL (1) | IL250484B (en) |
| LT (1) | LT3186240T (en) |
| MX (1) | MX2017002312A (en) |
| MY (1) | MY189098A (en) |
| NZ (1) | NZ729064A (en) |
| PH (1) | PH12017500290A1 (en) |
| PL (1) | PL3186240T3 (en) |
| PT (1) | PT3186240T (en) |
| SG (1) | SG11201700882XA (en) |
| SI (1) | SI3186240T1 (en) |
| TW (1) | TWI687409B (en) |
| WO (1) | WO2016031255A1 (en) |
| ZA (1) | ZA201700916B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI687409B (en) * | 2014-08-28 | 2020-03-11 | 日商大塚製藥股份有限公司 | Fused heterocyclic compounds |
| WO2017146246A1 (en) * | 2016-02-26 | 2017-08-31 | 大塚製薬株式会社 | Piperidine derivative |
| WO2019239382A1 (en) | 2018-06-15 | 2019-12-19 | Cadila Healthcare Limited | Condensed azaheteroaryl compounds having antibacterial activity against tuberculosis bacteria |
| JP2023085582A (en) * | 2020-05-11 | 2023-06-21 | 大塚製薬株式会社 | Cocrystal of dihydroquinolinone compound |
| EP4201407A1 (en) * | 2020-08-19 | 2023-06-28 | MitoImmune Therapeutics Inc. | Mitochondria-targeted antioxidant as agent for treating pathologic inflammation caused by mabc-r infection |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2608788B2 (en) * | 1988-10-31 | 1997-05-14 | 大塚製薬 株式会社 | Schizophrenia remedy |
| US5668127A (en) | 1995-06-26 | 1997-09-16 | Pathogenesis Corporation | Nitroimidazole antibacterial compounds and methods of use thereof |
| AR041198A1 (en) | 2002-10-11 | 2005-05-04 | Otsuka Pharma Co Ltd | COMPOUND 2,3-DIHIDRO-6-NITROIMIDAZO [2,1-B] OXAXOL, AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT |
| GB0319150D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Novel compounds |
| CN100497345C (en) * | 2003-10-31 | 2009-06-10 | 大塚制药株式会社 | 2, 3-dihydro-6-nitroimidazolo [2,1-b] oxazole compounds for the treatment of tuberculosis |
| AU2004285811B2 (en) * | 2003-10-31 | 2008-06-12 | Otsuka Pharmaceutical Co., Ltd. | 2,3-dihydro-6-nitroimidazo (2,1-B) oxazole compounds for the treatment of tuberculosis |
| JP4761756B2 (en) | 2003-10-31 | 2011-08-31 | 大塚製薬株式会社 | 2,3-Dihydroimidazo [2,1-b] oxazole compound |
| ME02156B (en) * | 2004-06-24 | 2015-10-20 | Vertex Pharma | Modulators of atp-binding cassette transporters |
| EP2520567A3 (en) | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| GB0812648D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| WO2010045987A1 (en) * | 2008-10-23 | 2010-04-29 | Glaxo Group Limited | Substituted (aza) -1-methyl-1h-quin0lin-2-0nes as antibacterials |
| KR101738868B1 (en) | 2009-07-31 | 2017-05-23 | 글로벌 알리앙스 포 티비 드럭 디벨롭먼트 | Nitroimidazooxazine and nitroimidazooxazole analogues and their uses |
| US9051333B2 (en) | 2011-04-15 | 2015-06-09 | Otsuka Pharmaceutical Co., Ltd. | 6,7-dihydroimidazo [2,1-b] [1,3]oxazine bactericides |
| TWI687409B (en) * | 2014-08-28 | 2020-03-11 | 日商大塚製藥股份有限公司 | Fused heterocyclic compounds |
| WO2017146246A1 (en) * | 2016-02-26 | 2017-08-31 | 大塚製薬株式会社 | Piperidine derivative |
-
2015
- 2015-08-27 TW TW104128109A patent/TWI687409B/en active
- 2015-08-27 AR ARP150102746A patent/AR101704A1/en active IP Right Grant
- 2015-08-28 AP AP2017009788A patent/AP2017009788A0/en unknown
- 2015-08-28 MY MYPI2017700649A patent/MY189098A/en unknown
- 2015-08-28 PL PL15763096T patent/PL3186240T3/en unknown
- 2015-08-28 DK DK15763096.3T patent/DK3186240T3/en active
- 2015-08-28 SI SI201530868T patent/SI3186240T1/en unknown
- 2015-08-28 LT LTEP15763096.3T patent/LT3186240T/en unknown
- 2015-08-28 KR KR1020177007855A patent/KR102418413B1/en active IP Right Grant
- 2015-08-28 JP JP2017507903A patent/JP6625612B2/en active Active
- 2015-08-28 US US15/506,887 patent/US10053446B2/en active Active
- 2015-08-28 ES ES15763096T patent/ES2743788T3/en active Active
- 2015-08-28 MX MX2017002312A patent/MX2017002312A/en active IP Right Grant
- 2015-08-28 CA CA2959478A patent/CA2959478C/en active Active
- 2015-08-28 EP EP15763096.3A patent/EP3186240B9/en active Active
- 2015-08-28 AU AU2015307873A patent/AU2015307873B2/en active Active
- 2015-08-28 HU HUE15763096A patent/HUE045025T2/en unknown
- 2015-08-28 CN CN201580045974.4A patent/CN106795117B/en active Active
- 2015-08-28 NZ NZ729064A patent/NZ729064A/en unknown
- 2015-08-28 BR BR112017003231-7A patent/BR112017003231B1/en active IP Right Grant
- 2015-08-28 WO PCT/JP2015/004371 patent/WO2016031255A1/en active Application Filing
- 2015-08-28 SG SG11201700882XA patent/SG11201700882XA/en unknown
- 2015-08-28 EA EA201790464A patent/EA038414B1/en unknown
- 2015-08-28 PT PT15763096T patent/PT3186240T/en unknown
-
2017
- 2017-02-06 ZA ZA2017/00916A patent/ZA201700916B/en unknown
- 2017-02-07 IL IL250484A patent/IL250484B/en active IP Right Grant
- 2017-02-16 PH PH12017500290A patent/PH12017500290A1/en unknown
-
2018
- 2018-07-09 US US16/029,850 patent/US10464926B2/en active Active
-
2019
- 2019-08-16 HR HRP20191486TT patent/HRP20191486T2/en unknown
- 2019-08-26 CY CY20191100906T patent/CY1122286T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1243073A1 (en) | Therapeutic compounds and uses thereof | |
| IL247841A0 (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| ZA201607415B (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| GB201403093D0 (en) | Therapeutic compounds and their use | |
| IL251988A0 (en) | Glycan-interacting compounds and methods of use | |
| HRP20191486T1 (en) | Heterobicyclic compounds and their use for the treatment of tuberculosis | |
| IL283335B (en) | Dihydropyrimidin-2-one compounds and medical use thereof | |
| PT3089971T (en) | Compounds and methods of use | |
| IL251904B (en) | Apilimod for use in the treatment of melanoma | |
| IL249502A0 (en) | Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies | |
| EP3145525A4 (en) | Use of microperoxidases for the treatment of carboxyhemoglobinemia | |
| GB201403697D0 (en) | Compounds and methods of use | |
| GB201410387D0 (en) | Compounds and their therapeutic use | |
| GB201403496D0 (en) | Compounds and their therapeutic use |